Home  >  News
Eppen_CellXpert_Mar2026
you can get e-magazine links on WhatsApp. Click here
News
  Merck to present new data from cardio-pulmonary pipeline at the ACC.26 in New Orleans, from March 28-30,   March 17, 2026
  Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease,   March 17, 2026
  Lundbeck to present phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease at the 2026 AD/PD conference,   March 17, 2026
  Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints,   March 17, 2026
  Study affirms superiority of iMDx GraftAssure assay’s proprietary dd-cfDNA combination model score,   March 16, 2026
  Immutep to discontinue TACTI-004 phase III study of eftilagimod alfa in patients in 1st line non-small cell lung cancer,   March 16, 2026
  Aplagon doses first patient in phase 2a trial of APAC with peripheral arterial occlusive disease/chronic limb threatening ischemia,   March 14, 2026
  Meiji Seika Pharma and Foundation for Biomedical Research and Innovation begin phase I trial of ME3241 to evaluate safety & tolerability in Australia,   March 14, 2026
  Cbio receives European clearance to start human trial of next-generation T-cell therapy in late-stage cervical cancer,   March 14, 2026
  FreeDM2 randomized controlled trial shows Libre technology helps people with type 2 diabetes on basal insulin improve glucose management,   March 14, 2026
  Amydis receives phase 2 NIH grant award of $2.5 million to advance a novel approach to detect biomarker TDP-43,   March 13, 2026
  Citius Oncology reports positive results from phase 1 study of Lymphir in combo with pembrolizumab in relapsed or refractory gynaecologic cancers,   March 13, 2026
  Kainova reports positive results from phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in advanced solid tumours,   March 12, 2026
  EnteroBiotix completes patient enrolment in phase 2a trial of EBX-102-02 prior to allogeneic stem cell transplantation,   March 12, 2026
  VS3 Medical begins patient enrollment in FIH study of novel neurovascular implant to address symptomatic venous sinus stenosis,   March 11, 2026
  Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial,   March 11, 2026
  Pfizer’s phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis,   March 11, 2026
  IDEAYA Biosciences begins patient dosing in phase 1 trial of IDE892, a potential best-in-class PRMT5 inhibitor for MTAP-deleted solid tumours,   March 10, 2026
  Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective,   March 10, 2026
  Aisa Pharma announces positive results from phase 2 RECONNOITER trial of cilnidipine in patients with systemic sclerosis-associated Raynaud's phenomenon,   March 09, 2026

  • Results Found: 16865
  • 1
    •  
  • 2
    •  
  • 3
    •  
  • 4
    •  
  • 5
    •  
  • Go to
  • Total Number of Pages: 844
 Back
 
Propak_Asia_2026
CP_CPHI_Korea2026
IWE_CP_2026
ChemExpo_India_2026
PharmaTech_expo_Chandigarh2026
ASIA_PHARMA_EXPO_2026
CPHI_Japan26
Ana_Lab_India_2026
PharmaCore_India_2026
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram